Minao Tang
Overview
Explore the profile of Minao Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
74
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scaramozza M, Ruet A, Chiesa P, Ahamada L, Bartholome E, Carment L, et al.
JMIR Form Res
. 2024 Nov;
8:e60673.
PMID: 39515815
Background: Smartphones and wearables are revolutionizing the assessment of cognitive and motor function in neurological disorders, allowing for objective, frequent, and remote data collection. However, these assessments typically provide a...
2.
Scaramozza M, Chiesa P, Zajac L, Sun Z, Tang M, Juraver A, et al.
Mult Scler
. 2024 Jun;
30(9):1193-1204.
PMID: 38912764
Background: The Konectom™ smartphone-based cognitive processing speed (CPS) test is designed to assess processing speed and account for impact of visuomotor function on performance. Objective: Evaluate reliability and validity of...
3.
Oyama K, Giugliano R, Ruff C, Berg D, Jarolim P, Tang M, et al.
Eur J Heart Fail
. 2023 Mar;
25(6):832-841.
PMID: 36987929
Aims: Cardiac functional and structural remodelling in patients with atrial fibrillation (AF) contributes to development of heart failure (HF) as their major cardiovascular comorbidity. Circulating biomarkers may reflect these cardiac...
4.
Fagundes Jr A, Morrow D, Oyama K, Furtado R, Zelniker T, Tang M, et al.
J Am Coll Cardiol
. 2022 Aug;
80(9):887-897.
PMID: 36007987
Background: Biomarkers are known to predict major adverse cardiovascular events. However, the association of biomarkers with complex coronary revascularization procedures or high-risk coronary anatomy at the time of revascularization is...
5.
Furtado R, Fagundes Jr A, Oyama K, Zelniker T, Tang M, Kuder J, et al.
Circ Cardiovasc Interv
. 2022 Feb;
15(3):e011382.
PMID: 35209731
Background: Patients with prior percutaneous coronary intervention (PCI) are at high residual risk for multiple types of coronary events within and beyond the stented lesion. This risk might be mitigated...
6.
Oyama K, Giugliano R, Tang M, Bonaca M, Saver J, Murphy S, et al.
Eur Heart J
. 2021 Sep;
42(47):4821-4829.
PMID: 34537830
Aims: We assessed the impact of the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab on acute arterial events across all vascular territories, including coronary, cerebrovascular, and peripheral vascular beds,...
7.
Berg D, Giugliano R, Ruff C, Tang M, Im K, Jarolim P, et al.
J Am Coll Cardiol
. 2021 Aug;
78(6):634-636.
PMID: 34353540
No abstract available.
8.
Marston N, Oyama K, Jarolim P, Tang M, Sever P, Keech A, et al.
Circulation
. 2021 Jul;
144(3):249-251.
PMID: 34279993
No abstract available.
9.
Keech A, Oyama K, Sever P, Tang M, Murphy S, Hirayama A, et al.
Circ J
. 2021 May;
85(11):2063-2070.
PMID: 33980763
Background: There are concerns that Asian patients respond differently to some medications. This study evaluated the efficacy and safety of evolocumab among Asian vs. other subjects in the FOURIER trial,...
10.
Oyama K, Giugliano R, Berg D, Ruff C, Jarolim P, Tang M, et al.
Eur Heart J
. 2021 Mar;
42(17):1698-1706.
PMID: 33760027
Aims: We investigated whether patients with atrial fibrillation (AF) demonstrate detectable changes in biomarkers including high-sensitivity troponin T (hsTnT), N-terminal B-type natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15) over...